Primmune Therapeutics' Option/Warrant Round

Primmune Therapeutics raised a round of funding on November 08, 2017.

Primmune Therapeutics is developing an orally administered toll-like receptor 7 (TLR7) agonist for systemic activation of innate immunity.…

Articles about Primmune Therapeutics' Option/Warrant Round: